Transcriptome profiling of human myogenic progenitors following treatment with nicotinamide (NAM) or pyridoxine (PN) or the combination (NAM/PN).

Working with primary human myogenic progenitors (hMPs), we developed a high-content screen to discover molecules that enhanced myogenic function and identified NAM and PN as modulators of myogenic proliferation and differentiation. We characterized genome-wide expression profiles of NAM-, PN-treated and NAM/PN-treated hMPs with the goal to uncover the mechanisms of action of NAM and PN and the potential additivity from the combination at the molecular level in hMPs. hMPs (commercially available from Lonza) were treated with either 1% DMSO (vehicle), 1mM of nicotinamide, or 1mM of pyridoxine or the combination for 72 hours in growth medium (AmsBio). We performed biological replicates on 5 different donors for each treatment condition.

本研究以人类原代成肌祖细胞（primary human myogenic progenitors, hMPs）为实验材料，开发了一种高内涵筛选方法以挖掘可增强成肌功能的小分子，并鉴定出烟酰胺（NAM）与吡哆醇（PN）作为成肌增殖与分化的调节因子。我们对经NAM、PN单独处理及二者联合处理的hMPs进行了全基因组表达谱分析，旨在揭示NAM与PN的作用机制，以及二者联合使用在hMPs中潜在的分子水平加和效应。本研究使用的hMPs购自龙沙（Lonza）公司，将其分别以1%二甲基亚砜（DMSO，溶媒对照）、1mM烟酰胺、1mM吡哆醇或上述药物联合处理，于AmsBio公司生产的生长培养基中培养72小时。我们针对每一种处理条件，设置了来自5名不同人类供体的生物学重复。